Multivariate Cox analysis: predictive effect of Day100 score on cGVHD, TRM, and survival in the training set
| . | cGVHD . | TRM . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Day100 score | |||||||||
| Int. vs low | 2.02 | 1.26-3.24 | .003 | 2.05 | 1.18-3.50 | .009 | 1.24 | 0.93-1.64 | .13 |
| High vs low | 6.43 | 3.58-11.58 | <.0001 | 3.57 | 1.80-7.03 | .0003 | 1.49 | 0.96-2.30 | .07 |
| Karnofsky <90% | — | — | — | — | — | — | 1.50 | 1.15-1.94 | .002 |
| Diagnosis AL vs other | — | — | — | — | — | — | 1.60 | 1.26-2.03 | .0001 |
| Year of transplant | |||||||||
| 2000-2009 vs <2000 | 0.39 | 0.26-0.59 | <.0001 | 0.53 | 0.34-0.84 | .007 | 0.72 | 0.54-0.95 | .02 |
| 2010-2016 vs <2000 | 0.54 | 0.36-0.81 | .003 | 0.46 | 0.27-0.79 | .005 | 0.60 | 0.44-0.83 | .002 |
| no CR vs CR | — | — | — | — | — | — | 2.44 | 1.89-3.15 | <.0001 |
| Donor sex F→M vs other | 1.55 | 1.08-2.21 | .04 | 1.71 | 1.11-2.65 | .01 | — | — | — |
| aGVHD II-IV | 1.66 | 1.13-2.43 | .008 | — | — | — | — | — | — |
| Cy post: yes vs no | — | — | — | — | — | — | |||
| ATG: yes vs no | — | — | — | — | — | — | |||
| Stem cell source | |||||||||
| PB vs BM | 1.58 | 0.94-2.42 | .06 | — | — | — | |||
| CB vs BM | — | — | — | — | — | — | |||
| Recipient age yy (cont) | — | — | — | 1.02 | 1.00-1.03 | .01 | 1.01 | 1.00-1.02 | .0001 |
| Donor age yy (cont) | — | — | — | ||||||
| . | cGVHD . | TRM . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Day100 score | |||||||||
| Int. vs low | 2.02 | 1.26-3.24 | .003 | 2.05 | 1.18-3.50 | .009 | 1.24 | 0.93-1.64 | .13 |
| High vs low | 6.43 | 3.58-11.58 | <.0001 | 3.57 | 1.80-7.03 | .0003 | 1.49 | 0.96-2.30 | .07 |
| Karnofsky <90% | — | — | — | — | — | — | 1.50 | 1.15-1.94 | .002 |
| Diagnosis AL vs other | — | — | — | — | — | — | 1.60 | 1.26-2.03 | .0001 |
| Year of transplant | |||||||||
| 2000-2009 vs <2000 | 0.39 | 0.26-0.59 | <.0001 | 0.53 | 0.34-0.84 | .007 | 0.72 | 0.54-0.95 | .02 |
| 2010-2016 vs <2000 | 0.54 | 0.36-0.81 | .003 | 0.46 | 0.27-0.79 | .005 | 0.60 | 0.44-0.83 | .002 |
| no CR vs CR | — | — | — | — | — | — | 2.44 | 1.89-3.15 | <.0001 |
| Donor sex F→M vs other | 1.55 | 1.08-2.21 | .04 | 1.71 | 1.11-2.65 | .01 | — | — | — |
| aGVHD II-IV | 1.66 | 1.13-2.43 | .008 | — | — | — | — | — | — |
| Cy post: yes vs no | — | — | — | — | — | — | |||
| ATG: yes vs no | — | — | — | — | — | — | |||
| Stem cell source | |||||||||
| PB vs BM | 1.58 | 0.94-2.42 | .06 | — | — | — | |||
| CB vs BM | — | — | — | — | — | — | |||
| Recipient age yy (cont) | — | — | — | 1.02 | 1.00-1.03 | .01 | 1.01 | 1.00-1.02 | .0001 |
| Donor age yy (cont) | — | — | — | ||||||
AL, acute leukemia; ATG, anti-thymocyte globulins; CB, cord blood; (cont), continuous variable; CR, complete remission; Cy-post, cyclophosphamide post-transplant; F, female; Haplo, haploidentical donor; M, male; MAC, myeloablative conditioning; MMF, micophenolic acid; MTX, methotrexate; MUD, matched unrelated donor; RIC, reduced intensity conditioning; SIB, relative fully-matched donor.